Craft

Inozyme

Stock Price

$4.6

2024-10-29

Market Capitalization

$310 M

2024-10-29

Inozyme Summary

Company Summary

Overview
Inozyme is a biopharmaceutical company specializing in the developing of novel therapeutics to treat rare metabolic diseases. The Company's area of expertise is disorders of paradoxical mineralization and its lead drug is an enzyme replacement therapy in pre-clinical development.
Type
Public
Status
Active
Founded
2016
HQ
Boston, MA, US | view all locations
Website
http://www.inozyme.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Doug Treco

    Doug Treco, Chairman

    • Joseph Schlessinger

      Joseph Schlessinger, Member of Scientific Advisory Board

      • Reinaldo M. Diaz
      • Gayle Gironda

        Gayle Gironda, Senior Vice President and Chief People Officer

      LocationsView all

      3 locations detected

      • Boston, MA HQ

        United States

        321 Summer St #400

      • Boston, MA

        United States

        321 Summer St floor 4

      • Boston, MA

        United States

        451 D St #911

      Inozyme Financials

      Summary Financials

      Net income (Q1, 2025)
      ($28.0M)
      Cash (Q1, 2025)
      $25.8M
      EBIT (Q1, 2025)
      ($27.7M)
      Enterprise value
      $330.4M

      Footer menu